Kura Oncology Stock Forecast, Price & News

-0.05 (-0.22 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume730,789 shs
Average Volume710,998 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Kura Oncology logo

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.23 out of 5 stars

Medical Sector

935th out of 2,100 stocks

Pharmaceutical Preparations Industry

453rd out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Kura Oncology

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04.
View Kura Oncology's earnings history

How has Kura Oncology's stock price been impacted by Coronavirus?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 132.6% and is now trading at $22.45.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KURA?

9 brokers have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $33.00 to $56.00. On average, they expect Kura Oncology's stock price to reach $42.56 in the next twelve months. This suggests a possible upside of 89.6% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 52, Pay $908.26k)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer (Age 48, Pay $630.86k)
  • Ms. Kathleen Ford, Chief Operating Officer (Age 74, Pay $492.28k)
  • Mr. James E. Basta J.D., Esq., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $168.94k)
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
  • Dr. Blake Tomkinson M.B.A., Ph.D., Head of Portfolio Strategy & Program Management
  • Ms. Kirsten Flowers, Chief Commercial Officer (Age 46)
  • Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
  • Dr. Stephen Dale M.D., Chief Medical Officer (Age 49)
  • Dr. Nic G. Scalfarotto, Sr. VP of Regulatory Affairs

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.88%), EcoR1 Capital LLC (5.57%), Ameriprise Financial Inc. (3.73%), Holocene Advisors LP (3.38%), Victory Capital Management Inc. (2.52%) and BVF Inc. IL (2.47%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Credit Suisse AG, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Federated Hermes Inc., D. E. Shaw & Co. Inc., Acuta Capital Partners LLC, and JPMorgan Chase & Co.. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology
or view top insider-selling stocks.

Which major investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Ameriprise Financial Inc., Holocene Advisors LP, Suvretta Capital Management LLC, BVF Inc. IL, BlackRock Inc., Ghost Tree Capital LLC, and Sphera Funds Management LTD..
View insider buying and selling activity for Kura Oncology
or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $22.45.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $1.49 billion. The company earns $-89,630,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 88 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.